cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Enzymes like proteases, lipases, and amylases have an important role in the soaking, dehairing, degreasing, and bating operations of leather manufacturing. Proteases are the most commonly used enzymes in leather production. The enzyme must not damage or dissolve collagen or keratin, but should hydrolyze casein, elastin, albumin, globulin-like proteins, and nonstructural proteins that are not essential for leather making. This process is called bating. Lipases are used in the degreasing operation to hydrolyze fat particles embedded in the skin. Amylases are used to soften skin, to bring out the grain, and to impart strength and flexibility to the skin. These enzymes are rarely used.
== Interactions == There are several notable drug interactions with progesterone. Certain selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, and sertraline may increase the GABAA receptor-related central depressant effects of progesterone by enhancing its conversion into 5α-dihydroprogesterone and allopregnanolone via activation of 3α-HSD. Progesterone potentiates the sedative effects of benzodiazepines and alcohol. Notably, there is a case report of progesterone abuse alone with very high doses. 5α-Reductase inhibitors such as finasteride and dutasteride inhibit the conversion of progesterone into the inhibitory neurosteroid allopregnanolone, and for this reason, may have the potential to reduce the sedative and related effects of progesterone. Progesterone is a weak but significant agonist of the pregnane X receptor (PXR), and has been found to induce several hepatic cytochrome P450 enzymes, such as CYP3A4, especially when concentrations are high, such as with pregnancy range levels. As such, progesterone may have the potential to accelerate the metabolism of various medications.
Together with his close collaborator Richard DiMarchi (Indiana University) he discovered and validated the novel drug class of dual and triple gut hormone co-agonists for the treatment of obesity and diabetes, and was also a co-founder of a biotechnology company MB2 LLC that was successfully acquired by Novo Nordisk in 2015. These new drugs simultaneously target several receptors and reduce body weight and blood sugar with unprecedented efficacy. Several of these compounds are in clinical trials for the treatment of diabetes and obesity and one representative of this drug class, the GIP/GLP1 receptor dual agonist Tirzepatide (Mounjaro, Eli Lilly and Company) was FDA approved for diabetes in 2022. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations. In 2022, Tschöp was a candidate to succeed Heinz Engl as rector of the University of Vienna; however, he ultimately withdrew his application.
== Research == Oral administration of LGD-4033 to cynomolgus monkeys at daily doses varying from 0 to 75 mg/kg over 13 weeks demonstrated significant body weight gain in both males and females. After 48 days, the 75 mg/kg dose testing was halted due to toxicity concerns, but this did not negatively impact development of the drug as this dose is significantly higher than the doses being utilized in a phase 2 clinical trial. Two phase 1 clinical trials of LGD-4033 have been conducted and reported. The first was a single-dose study published as a conference abstract in 2010 and the second was a multi-dose study published as a journal article in 2013. The multi-dose phase 1 trial published in 2013 reported that LGD-4033 dose-dependently improved lean body mass and muscle strength in 76 healthy young men over 21 days. It was generally well-tolerated in this study, with no significant adverse effects reported. A phase 2 clinical trial, initiated on 3 November 2016, consisted of 108 women and men recovering from hip fracture surgery. The randomized study participants received either placebo or varying doses of LGD-4033 over a period of 12 weeks, with improved lean body mass as the primary endpoint. Other endpoints included satisfactory results in terms of quality of life, safety, and pharmacokinetics. This study was completed and results reported in 2017 and 2018. In the trial, LGD-4033 dose-dependently improved lean body mass and muscle strength and was reported to be safe and well-tolerated.
However, its toxicity to microorganisms is not overtly observed since the free silver ion is found in low concentrations in wastewater treatment systems and the natural environment due to its complexation with ligands such as chloride, sulfide, and thiosulfate.
Sources: en.wikipedia.org
== Activity and regulation == Cells typically maintain low NADP+/NADPH ratios by rapidly reducing NADP+ to NADPH using glutathione reductase in a cyclical NADPH replenishing reaction. These cells rapidly reduce ambient 5-oxo-ETE to 5(S)-HETE. However, cells suffering oxidative stress generate excesses in toxic reactive oxygen species such as hydrogen peroxide (H2O2). Cells use glutathione peroxidase to detoxify this H2O2 by converting it to H2O in a reaction that consumes glutathione by converting it to glutathione disulfide; the cells then metabolize glutathione disulfide back to glutathione in a glutathione reductase-dependent reaction that converts NADPH to NADP+. While cells suffering oxidative stress can replenish NADPH by reducing NADP+ through the pentose phosphate pathway, they often develop very high NADP+/NADPH ratios and therefore preferentially convert 5-(S)-HETE to 5-oxo-ETE. Cells that function as phagocytes have a second pathway that dramatically raises NADP+/NADPH ratios. Neutrophils and macrophages, for example, after phagocytosing bacteria or otherwise strongly stimulated to activate their respiratory burst generate reactive oxygen species including H2O2 by activating NADPH. The latter cell types have particularly high levels of 5-HEDH and therefore are particularly important producers of 5-oxo-ETE when so stimulated. The death of neutrophils and tumor cells also strongly promotes the oxidation of 5-HETE to 5-oxo-ETE, probably as a result of associated oxidative stress.
The general detection scheme involves: Pneumatic nebulization of mobile phase from the analytical column forming an aerosol. Aerosol conditioning to remove large droplets. Evaporation of solvent from the droplets to form dried particles. Particle charging using an ion jet formed via corona discharge. Particle selection – an ion trap is used to excess ions and high mobility charged particles. Measurement of the aggregate charge of aerosol particles using a filter/electrometer. The CAD like other aerosol detectors, can only be used with volatile mobile phases. For an analyte to be detected it must be less volatile than the mobile phase. More detailed information on how CAD works can be found on the Charged Aerosol Detection for Liquid Chromatography Resource Center.
At least three isotopes of iodine are important. 129I, 131I (radioiodine) and 132I. Open air nuclear testing and the Chernobyl disaster both released iodine-131. The short-lived isotopes of iodine are particularly harmful because the thyroid collects and concentrates iodide – radioactive as well as stable. Absorption of radioiodine can lead to acute, chronic, and delayed effects. Acute effects from high doses include thyroiditis, while chronic and delayed effects include hypothyroidism, thyroid nodules, and thyroid cancer. It has been shown that the active iodine released from Chernobyl and Mayak has resulted in an increase in the incidence of thyroid cancer in the former Soviet Union. One measure which protects against the risk from radio-iodine is taking a dose of potassium iodide (KI) before exposure to radioiodine. The non-radioactive iodide "saturates" the thyroid, causing less of the radioiodine to be stored in the body. Administering potassium iodide reduces the effects of radio-iodine by 99% and is a prudent, inexpensive supplement to fallout shelters. A low-cost alternative to commercially available iodine pills is a saturated solution of potassium iodide. Long-term storage of KI is normally in the form of reagent-grade crystals. The administration of known goitrogen substances can also be used as a prophylaxis in reducing the bio-uptake of iodine, (whether it be the nutritional non-radioactive iodine-127 or radioactive iodine, radioiodine - most commonly iodine-131, as the body cannot discern between different iodine isotopes).
== Side effects == A significant side effect of insulin therapy is hypoglycemia. A meta-analysis of clinical trials published in July 2012 found 39 to 47.9 events of hypoglycemia (defined as blood glucose <56 mg/dL) per patient year, with higher rates in the more concentrated degludec formulation. Rates of nocturnal hypoglycemia ranged from 3.7 to 5.1 events per patient year. A more recent Cochrane systematic review found there was no significant differences in rates of diurnal, nocturnal hypoglycemia or any other studies outcomes when using insulin degludec as compared to insulin glargine, insulin detemir and NPH insulin for the management of type 1 diabetes in either adults or children.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.